Originally published by our sister publication Gastroenterology & Endoscopy News
The FDA has approved risankizumab (Skyrizi, AbbVie), an interleukin-23 inhibitor, for patients with moderate to severe ulcerative colitis. It is the first IL-23 inhibitor approved for treating both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.
The approval follows positive results from two multicenter randomized, double-blind, controlled, phase 3 clinical trials: the 12-week